Equipoise, Trust, and the Need for Cardiologists to Randomly Assign Patients Into Anticoagulation Trials in the Time of COVID

Circulation. 2020 Dec 15;142(24):2296-2298. doi: 10.1161/CIRCULATIONAHA.120.052069. Epub 2020 Oct 15.

Authors

Paul M Ridker¹, Thomas L Ortel², Judith S Hochman³

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, MA (P.M.R.).
² Duke University School of Medicine, Durham, NC (T.L.O.).
³ New York University Langone Health, New York (J.S.H.).

No abstract available

Keywords: COVID-19; clinical trial protocols; heparin; post-exposure prophylaxis; randomized controlled trial.

MeSH terms

Anticoagulants / therapeutic use*
Attitude of Health Personnel
COVID-19*
Cardiologists*
Humans
Patient Selection
Physician's Role*
Randomized Controlled Trials as Topic*

Substances

Anticoagulants